News >

FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma

Silas Inman @silasinman
Published: Monday, Jan 22, 2018

Jan van de Winkel, PhD

Jan van de Winkel, PhD
The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The designation was based on findings from the ALCYONE study, which were published in the New England Journal of Medicine and presented at the 2017 ASH Annual Meeting.1,2

<.001).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x